HUDDINGE, Sweden--(BUSINESS WIRE)--Regulatory News:
Presentations include late-breaking final results from the phase III OPTIMIST trials and interim results from the phase II IMPACT trial of simeprevir.
Medivir AB (Nasdaq Stockholm: MVIR) today announced that new clinical data for simeprevir, the NS3/4A protease inhibitor for the treatment of hepatitis C virus (HCV) infection, will be presented by our partner Janssen Sciences Ireland UC at The International Liver Congress™ 2015 of the European Association for the Study of the Liver (EASL) taking place in Vienna from April 22-26.
Help employers find you! Check out all the jobs and post your resume.
